E-viri
PDF
Recenzirano
Odprti dostop
-
Subhan, Md Abdus; Yalamarty, Satya Siva Kishan; Filipczak, Nina; Parveen, Farzana; Torchilin, Vladimir P.
Journal of personalized medicine, 06/2021, Letnik: 11, Številka: 6Journal Article
Cancer causes the second-highest rate of death world-wide. A major shortcoming inherent in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy administered intravenously escape renal clearance, are unable to penetrate through tight endothelial junctions of normal blood vessels and remain at a high level in plasma. Over time, the concentration of nanodrugs builds up in tumors due to the EPR effect, reaching several times higher than that of plasma due to the lack of lymphatic drainage. This review will address in detail the progress and prospects of tumor-targeting via EPR effect for cancer therapy.
